Evidence map›Paper›PMID 37504519›Full record

ArticleMicrobiology resource announcements2023

Matthew A Crawford, Christine Lascols, Sara Lomonaco, Ruth E Timme, Debra J Fisher, Kevin Anderson, David R Hodge, Stephen A Morse, Segaran P Pillai, Shashi K Sharma and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology resource announcements, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Antimicrobial agents and chemotherapy · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Matthew A CrawfordDivision of Infectious Diseases and International Health, Department of Medicine, University of Virginia , Charlottesville, Virginia, USA.ORCID 0000-0003-0404-0061
Christine LascolsNational Center for Emerging and Zoonotic Diseases, Centers for Disease Control and Prevention , Atlanta, Georgia, USA.
Sara LomonacoDivision of Microbiology, Office of Regulatory Science, Center for Food Safety and Applied Nutrition, US Food and Drug Administration , College Park, Maryland, USA.ORCID 0000-0001-8242-6280
Ruth E TimmeDivision of Microbiology, Office of Regulatory Science, Center for Food Safety and Applied Nutrition, US Food and Drug Administration , College Park, Maryland, USA.ORCID 0000-0002-9705-5897
Debra J FisherDivision of Infectious Diseases and International Health, Department of Medicine, University of Virginia , Charlottesville, Virginia, USA.
Kevin AndersonScience and Technology Directorate, US Department of Homeland Security , Washington, DC, USA.
David R HodgeScience and Technology Directorate, US Department of Homeland Security , Washington, DC, USA.
Stephen A MorseIHRC, Inc. , Atlanta, Georgia, USA.
Segaran P PillaiOffice of the Commissioner, US Food and Drug Administration , Silver Spring, Maryland, USA.
Shashi K SharmaDivision of Microbiology, Office of Regulatory Science, Center for Food Safety and Applied Nutrition, US Food and Drug Administration , College Park, Maryland, USA.
Erum KhanDepartment of Pathology and Microbiology, Aga Khan University , Karachi, Pakistan.
Marc W AllardDivision of Microbiology, Office of Regulatory Science, Center for Food Safety and Applied Nutrition, US Food and Drug Administration , College Park, Maryland, USA.
Molly A HughesDivision of Infectious Diseases and International Health, Department of Medicine, University of Virginia , Charlottesville, Virginia, USA.

Funding

A unique strategy for reshaping the antibiotics model: chemokine-inspired therapeutics for targeting the host and pathogen to counter infections caused by multidrug-resistant bacteriaR01AI150941 · NIAID · UNIVERSITY OF VIRGINIA · PI HUGHES, MOLLY A · 2020 to 2024
$3.1M
Elucidating a unique bacterial strategy that protects susceptible bacteria from antibiotic killing and promotes the genetic transmission of antimicrobial resistanceR21AI139947 · NIAID · UNIVERSITY OF VIRGINIA · PI HUGHES, MOLLY A · 2018 to 2019
$451k
NIAID NIH HHS R01 AI150941NIAID NIH HHS R21 AI139947
6 · The paper itself

Abstract

The continued emergence and spread of antimicrobial resistance among pathogenic bacteria are ever-growing threats to health and economy. Here, we report the draft genomes for 45

Indexed as

AMRFinderPlusantimicrobial resistanceEnterobacterEnterobacteralesKlebsiellaPakistanSalmonellaSerratiawhole-genome sequencing

Identifiers

PMID37504519
PMCPMC10508161

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.